Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (61-70 of 1,421) with videos related to

Pageof 143
Sort By:
Journal of Cardiac Failure|April 19, 2021
Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart FailureScott D Solomon, John J V McMURRAY
The New England Journal of Medicine|March 19, 2020
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. ReplyScott D Solomon, John J V McMurray,
Circulation|March 27, 2020
Applying the Lessons of Influenza to COVID-19 During a Time of UncertaintyOrly Vardeny, Mohammad Madjid, Scott D Solomon
Circulation|August 27, 2022
DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart FailureCarolyn S P Lam, Scott D Solomon
Journal of the American College of Cardiology|June 25, 2021
Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the WeekCarolyn S P Lam, Scott D Solomon
JACC. Heart Failure|November 4, 2017
Reply: An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin InhibitionScott D Solomon, John J V McMurray,
JAMA Cardiology|October 16, 2024
Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target-ReplyAlexander Peikert, Scott D Solomon, Orly Vardeny
JACC. Heart Failure|October 13, 2014
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureOrly Vardeny, Ryan Miller, Scott D Solomon
JAMA Cardiology|November 18, 2020
Complications in Patients With COVID-19-ReplyMohammad Madjid, Scott D Solomon, Orly Vardeny
Journal of the American College of Cardiology|July 6, 2019
Reply: Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNIPeder Langeland Myhre, Muthiah Vaduganathan, Scott D Solomon, et al.
Pageof 143

Showing results (61-70 of 1,421) with videos related to

Sort By:
Pageof 143
Journal of Cardiac Failure|April 19, 2021
Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart FailureScott D Solomon, John J V McMURRAY
The New England Journal of Medicine|March 19, 2020
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. ReplyScott D Solomon, John J V McMurray,
Circulation|March 27, 2020
Applying the Lessons of Influenza to COVID-19 During a Time of UncertaintyOrly Vardeny, Mohammad Madjid, Scott D Solomon
Circulation|August 27, 2022
DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart FailureCarolyn S P Lam, Scott D Solomon
Journal of the American College of Cardiology|June 25, 2021
Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the WeekCarolyn S P Lam, Scott D Solomon
JACC. Heart Failure|November 4, 2017
Reply: An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin InhibitionScott D Solomon, John J V McMurray,
JAMA Cardiology|October 16, 2024
Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target-ReplyAlexander Peikert, Scott D Solomon, Orly Vardeny
JACC. Heart Failure|October 13, 2014
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureOrly Vardeny, Ryan Miller, Scott D Solomon
JAMA Cardiology|November 18, 2020
Complications in Patients With COVID-19-ReplyMohammad Madjid, Scott D Solomon, Orly Vardeny
Journal of the American College of Cardiology|July 6, 2019
Reply: Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNIPeder Langeland Myhre, Muthiah Vaduganathan, Scott D Solomon, et al.
Pageof 143